News

The ‘intent to treat’ population of 22 patients included 13 with relapsing remitting multiple sclerosis (RRMS) and nine with secondary progressive multiple sclerosis (SPMS). An analysis of disease

Data from the second cohort of volunteers in a Phase I/IIa clinical trial sponsored by the US Naval Medical Research Center (NMRC) and the US Military Malaria Vaccine

The agent, CTC-96, also known as Doxovir, was developed by Redox Pharmaceutical. CTC-96’s novel antiviral mechanism has demonstrated efficacy against multiple viral infections in preclinical studies. CTC-96 has

The shares of common stock and warrants were offered in units consisting of one share of common stock and a warrant to purchase 0.20 shares of common stock

Mazal Plant Pharmaceuticals has also received approval to conduct a large-scale, double-blind, four-arm study in human subjects diagnosed with alphalipoproteinemia (subjects with low HDL). The subjects will be

Advanced Medical Isotope (AMIC) proposes development of a proprietary concept for controlled delivery of yttrium-90 (Y-90) microspheres embedded in resorbable seed-shape materials for tissue-directed, high-dose intra-tumoral therapy. According

This will be a multi-center, parallel arm placebo-controlled, clinical trial in which approximately 150 patients with bipolar disorder will receive either RG2417 or a placebo twice a day

Atlas was a randomized, placebo-controlled, double-blind, Phase III study conducted in the US and Europe. The study involved 315 patients with active ankylosing spondylitis (AS) who had an

The trial will be an open-label, Phase II study of IT-101 intended to demonstrate safety and efficacy in patients with relapsed or refractory lymphoma, and will be preceded